Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer

Sebastian Mondaca; Henry Walch; Subhiksha Nandakumar; Walid K Chatila; Nikolaus Schultz; Rona Yaeger

doi:10.1053/j.gastro.2020.07.041

Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer

Gastroenterology. 2020 Nov;159(5):1975-1978.e4. doi: 10.1053/j.gastro.2020.07.041. Epub 2020 Jul 27.

Authors

Sebastian Mondaca¹, Henry Walch², Subhiksha Nandakumar², Walid K Chatila³, Nikolaus Schultz⁴, Rona Yaeger⁵

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Tri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medical College, New York, New York.
⁴ Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
⁵ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: yaegerr@mskcc.org.

Abstract

In an integrated genomic and clinical analysis, we evaluate the effects of Wnt and DNA damage response pathway alterations on metastatic colorectal cancer.

Keywords: APC; Colorectal Cancer; DNA Damage Response.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adenomatous Polyposis Coli Protein / genetics*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor / genetics*
Clinical Decision-Making
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics*
Colorectal Neoplasms / mortality
Colorectal Neoplasms / pathology
DNA Damage*
DNA Mutational Analysis
Drug Resistance, Neoplasm
Genetic Predisposition to Disease
Humans
Mutation*
Neoplasm Metastasis
Phenotype
Precision Medicine
Progression-Free Survival
Time Factors

Substances

APC protein, human
Adenomatous Polyposis Coli Protein
Biomarkers, Tumor

Abstract

Publication types

MeSH terms

Substances

Grants and funding